Iparomlimab And Tuvonralimab Injection｜Cervical Cancer

Iparomlimab And Tuvonralimab Injection Application Scope

lparomlimab And Tuvonralimab Injection is indicated for the treatment of certain types of cancer, such as cervical cancer, non-small cell lung cancer (NSCLC) and melanoma. It works by targeting specific immune checkpoints, such as the PD-1/PD-L1 pathway, to boost the patient’s own immune system and thereby inhibit tumor growth.

Iparomlimab And Tuvonralimab InjectionCharacteristics

• Ingredients: lparomlimab And Tuvonralimab
• Properties: fluids
• Specification: 150 mg per vial (or based on concentration per dose)
• Storage: Store at 2-8°C (36-46°F)
• Packaging Specification: single-use vials, pre-filled syringes
• Expiry Date: 24 months from the manufacturing date
• Executive Standard:China Pharmacopeia, international standards like ICH guidelines
• Approval Number: (Refer to the NMPA approval number or any international regulatory references if applicable)
• Date of Revision: the date of the last revision on the drug’s information package
• Manufacturer: Qilu Pharmaceutical

Guidelines For The Use Of Iparomlimab And Tuvonralimab Injection

 

Dosage and Administration:

5.0 mg/kg once every 3 weeks (Q3W) Injection therapy

Adverse Reactions:

Common adverse reactions: fatigue, rash, loss of appetite, and nausea.
Serious adverse reaction: possible immune-related pneumonia, hepatitis, and colitis.

Contraindications:

Contraindicated in persons who are hypersensitive to the active ingredient or any excipient of this product.
Use with caution in patients with severe immune system disorders.

Precautions:

A thorough immune system evaluation is required prior to use.
Monitor liver and kidney function and blood counts regularly during treatment.
Use with caution in pregnant and lactating women, the pros and cons of which need to be weighed.

Iparomlimab And Tuvonralimab Injection Interactions

Drug Interactions:

Combination with other immunosuppressive agents may increase the risk of infection.
Combination with cytotoxic drugs may potentiate or diminish efficacy and requires close monitoring.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.